Avadel Pharmaceuticals Provides Comment on Recent Trading Activity
26 avr. 2022 07h30 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a...
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
25 avr. 2022 08h00 HE
|
Avadel Pharmaceuticals plc
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the twice-nightly dosing regimen for oxybatesNocturnal adverse event questionnaires...
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
06 avr. 2022 08h00 HE
|
Avadel Pharmaceuticals plc
Once-at-bedtime FT218 demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared to placebo in adults with narcolepsyNew data bolster positive primary endpoint...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
22 mars 2022 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
17 mars 2022 07h00 HE
|
Avadel Pharmaceuticals plc
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launch Expanded the robust portfolio of data supporting the potential impact of...
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
14 mars 2022 16h30 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th
14 mars 2022 08h00 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a...
Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
11 mars 2022 07h00 HE
|
Avadel Pharmaceuticals plc
Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly preferred...
Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 mars 2022 16h30 HE
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief...
Avadel to Present New Clinical Data at World Sleep 2022
01 mars 2022 07h00 HE
|
Avadel Pharmaceuticals plc
Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinical trial of FT218 and the RESTORE open-label extension/switch study of FT218 in addition to discrete...